IRF8 and prostate cancer: These CRC mapping methods, along with pharmacological and genomic studies, have identified critical roles for MYOD, IRF8, FOXA1, and SOX11 TFs in rhabdomyosarcoma, acute myeloid leukaemia (AML), prostate cancer, and neuroblastoma [22,27,32,33], respectively.